Board

Timm-H. Jessen, PhD

 

Timm-H. Jessen ist founder and Chief Executive Officer of SCIENAMICS GmbH, a consultancy focused on marketing and business development for biotech and pharmaceutical companies. Before founding SCIENAMICS, he was Chief Scientifc Officer of Evotec OAI AG for several years and held various positions at Hoechst, then Sanofi-Aventis. He was part of the Biotech Integration Team throughout the merger with Roussell and Marion Merrell Dow and became Head of Biotechnology for Hoechst Marion Roussell, Germany before he moved to Evotec OAI. Timm-H. Jessen was trained in chemistry and biochemistry, graduated at the University of Kiel and received his PhD from the University of Munich (Max Planck Institute for Biochemistry).

 

Joachim (JR) Rothe, PhD

 

Joachim (JR) Rothe PhD is responsible for LSP’s German office in Munich, and serves or has served on the supervisory boards of Bioxell (I/CH), Affectis (D),  U3 Pharma (D), IDEA (D) and Okairos (CH). Before joining LSP as a general partner in early 2002, he was a principal at MPM Capital in Cambridge, MA, USA, and Managing Director of MPM Capital GmbH based in Munich. In that capacity, Joachim served on the supervisory boards of Novirio Pharmaceuticals (now: Nasdaq: IDIX), OMRIX Biopharmaceuticals (now: Nasdaq: OMRI) and t. Breeders (now: Nasdaq: VIAC), and he was significantly involved in the Biovitrum (SSE: BVT) and Cellular Genomics transactions.
Previously, Joachim worked at McKinsey & Company where he was an engagement manager on assignments in the chemical and pharmaceutical industries. He also spent time at Hoffmann-La Roche in Basel, Switzerland, where he worked in both the preclinical development department as well as in central research. Joachim, a German native, has a Masters degree in biochemistry from the Free University in Berlin, and a PhD degree from the University of Freiburg. He has authored numerous articles in leading scientific publications, including Nature.